At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 249 enrolled
Drug / intervention
EDP1815 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Cohort, Dose-Ranging Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating EDP1815 and Placebo for Psoriasis and Plaque Psoriasis. Completed, enrolled 249 participants across 29 sites in 4 countries.
Detailed Summary
This Phase 2 study has been designed to investigate the clinical safety and efficacy of EDP1815 and to identify an optimal dose in subjects with mild to moderate psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis, Plaque Psoriasis
CountriesHungary, Poland, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartSep 2020
First PostedOct 2020
Primary CompletionJul 2021
Study CompletionDec 2021
TodayJul 2026
First PostedOct 26, 2020
Enrollment StartSep 21, 2020
Primary CompletionJul 2, 2021
Study CompletionDec 6, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 5.7 years ago
Interventions
EDP1815drug
EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
Placebodrug
Placebo oral capsule